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A B S T R A C T
Purpose
In February 2000, the criteria for measuring tumor shrinkage as an indicator of antitumor activity
were redefined by the Response Evaluation Criteria in Solid Tumors (RECIST). This resulted in
simplifying bidimensional to unidimensional measurement of lesions. Under RECIST, all lesions,
up to 10, must be measured. Scanning and measuring multiple lesions is costly, time-consuming,
and a disincentive to participation in clinical trials. We investigated whether fewer than 10 lesions
can be measured without compromising the accuracy of assessing a regimen’s activity.
Patients and Methods
Thirty-two North Central Cancer Treatment Group trials including 2,374 patients were analyzed.
Twelve studies were conducted before RECIST; 20 were conducted post-RECIST. Agreement
between objective status by cycle, confirmed response, overall response rate, and time to
progression (TTP) was evaluated based on all 10 versus the largest one through five lesions.
Results
The median number of lesions reported on RECIST trials did not differ from pre-RECIST trials
(median  2.0). One lesion at baseline was reported in 49% of patients, two lesions in 28% of
patients, three lesions in 12% of patients, four lesions in 6% of patients, and five lesions in 5%
of patients in post-RECIST trials. Utilizing the largest two lesions produced excellent concordance
with that using all lesions for all end points. In no trial did the overall response rate differ by more
than 3% when two versus all lesions were considered. Evaluating more than two lesions did not
significantly improve agreement.
Conclusion
Based on these trials, the assessment of more than two lesions did not alter the conclusions
regarding a treatment’s efficacy as judged by response rate or TTP.
J Clin Oncol 27:3205-3210. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Anticancer cytotoxic agents are often evaluated for
antitumor activity by measuring tumor shrinkage.
In the late 1970s, the International Union Against
Cancer and the WHO introduced specific criteria
for the codification of tumor response evaluation.
Over time, various groups developed diverging cri-
teria for the assessment of tumor response. In 1994,
the European Organisation for Research and Treat-
ment of Cancer (EORTC), the National Cancer In-
stitute (NCI) of the United States, and the National
Cancer Institute of Canada Clinical Trials Group
(NCIC CTG) established a task force—the Response
Evaluation Criteria in Solid Tumors (RECIST) —to
review existing criteria for evaluating response in
solid tumors resulting in a consensus document.1
RECIST is intended for trials where tumor response
is the primary end point, helps to further standardize
definitions and methodology, and simplifies data
collection by eliminating the need for bidimensional
measurements. RECIST is also an essential element
of clinical trials assessing time to tumor progression
(TTP), as in those trials, a progression event is typi-
cally defined using RECIST.
One element of RECIST was a standardiza-
tion of the number of lesions per patient required
to be evaluated. Under RECIST, all lesions, up to a
maximum of 10 lesions with a maximum of five
per organ, must be evaluated and reported. We are
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unaware of data to support the choice of 10. This requirement raises
multiple issues in the practical conduct of clinical trials. Specifically,
there is a concern that payers may not be willing to reimburse for the
scans necessary to follow up to 10 lesions, particularly if all scans would
not otherwise be required for routine clinical care. In addition, the cost
of collecting, processing, and auditing the additional data is substan-
tial. Difficulty with compliance is also a concern, as well as the poten-
tial for a negative effect on participation rates for trials requiring the
RECIST. The NCIC CTG Clinical Research Associate Committee
cited tumor measurements as a major factor contributing to in-
creased workload.2
Tumor shrinkage and TTP continue to be critical end points in
most clinical trials. The United States Food and Drug Administration
has consistently recognized tumor shrinkage as a measure of clinical
activity, and has allowed this evidence to be the basis for accelerated
approval of cancer drugs in some situations.3 In addition to tumor
response, TTP, or the closely related end point of progression-free
survival, are being increasingly used as a clinical trial end point. These
two considerations—the need to reduce the burden of clinical trials
and the continued importance of tumor assessments—imply that
determining the minimum number of tumor measurements that can
be assessed without compromising an accurate reflection of a regi-
men’s activity is critical.
Based on these considerations, we performed a retrospective
pooled analysis of NCCTG phase II/III clinical trials. The primary aim
of this analysis is to answer the question—can we assess fewer than 10
lesions without compromising an accurate reflection of a regi-
men’s activity?
PATIENTS AND METHODS
Individual patient data on 2,374 patients were pooled from 32 trials con-
ducted by the NCCTG open between August of 1998 and September of
2002. All trials that opened between these dates that collected radiographic
measurement data were included. A single trial, trial 96-32-55, did not have
adequate measurement data collected to allow inclusion.4 All trials and all
patient data collected as of September 20, 2002, were included for this analysis
regardless of data maturity. Twelve trials were conducted before implementa-
tion of the RECIST (pre-RECIST), 20 were post-RECIST implementation.
Trials included 12 GI trials, 10 lung trials, seven breast trials, two melanoma
trials, and one mesothelioma trial. Data were largely collected from patients
enrolled through NCCTG, but also included data from 925 patients enrolled to
NCCTG studies through other oncology cooperative groups including, Can-
cer and Leukemia Group B (CALGB; 323 patients), Southwest Oncology
Group (SWOG; 266 patients), Eastern Cooperative Oncology Group (ECOG;
212 patients), and the NCIC CTG (124 patients). Eighty-eight percent of the
patients (n  2,096) included in this analysis were evaluated using computer
tomography (CT), 4% with chest x-ray (n  88), 2% with physical examina-
tion (n  56), 0.9% with MRI (n  21), 0.2% with ultrasound (n  4), 3%
using a mix of imaging techniques (n  75), and 1% with unknown evaluation
techniques (n  34).
For patients entered onto pre-RECIST trials, measurable disease was
defined as lesions on physical examination or x-ray with clearly measurable
perpendicular diameters and/or liver edge at least 5 cm below the costal margin
lesions. Only measurable lesions were used for this analysis. For studies that
collected bidimensional measurements, the longer of the two measurements
for each lesion was used. The standard RECIST definitions were applied to
determine objective and progression status.1
Four end points were evaluated: per patient concordance between re-
ported objective status for each cycle; confirmed response per patient; TTP;
and the overall study response rate. To evaluate agreement, each end point was
compared based on all measured lesions for each patient versus the longest one
to five lesions for that same patient. For example, for the first end point,
objective status by cycle, the objective status (possible values of complete
response [CR], partial response [PR], stable disease, and disease progression)
based on all lesions reported was compared to the objective status computed
using only the longest lesion. This comparison was repeated for each evalua-
tion cycle. We performed similar comparisons of the objective status based on
all lesions with objective status based on the longest two, three, four, and five
lesions. Agreement was achieved when the objective status was consistent. An
objective status originally reported as a PR based on all lesions but calculated as
a CR when a subset of lesions was used was considered nonagreement. Any
evaluations where all measurements were not available were excluded for this
end point. Disease evaluations were conducted per protocol and included a
variety of evaluation schedules. Common schedules included every cycle, and
every other cycle starting with either cycle 1 or 2. Some protocols also require a
confirmation of initial response thus changing the schedule of evaluation once
an initial response is observed. The variability of these schedules results in a
different number of patients evaluated for objective status for each cycle. Due
to the most common schedule being every other cycle starting with cycle 2, this
time point has the largest number of patients with evaluations and is therefore
included as a representative example in the results section. Analyses were
conducted for cycles 1 to 6 in order to identify trends over the entire course
of treatment.
A response was considered confirmed if an objective status of CR or PR
was reported on two consecutive evaluations. Agreement was achieved when a
confirmed response was reported for a given patient based on all lesions and
was also computed when only the longest one to five lesions were considered,
or when a confirmed response was not reported for a given patient on all
reported lesions and based on the longest one to five lesions. Since the trials
analyzed were at different stages of data maturity, some patients had not yet
had two evaluations, such patients were excluded form analysis (n  267).
The cycle of progression was determined in all patients where a progres-
sion was reported in either the complete data (all lesions) or where a progres-
sion was calculated when considering only the longest one to five lesions. The
cycle in which a progression was first recorded using all reported lesions was
compared to the cycle in which a progression was first noted if only the longest
one to five lesions were considered. Agreement was achieved when the cycle of
progression was consistent. Patients were not included for this end point if they
were alive at the time of the analysis without a progression reported. Any
patients who died without progression or reported a progression based on the
presence of new lesions or clinical deterioration were considered an agreement
since the time of progression would not change based on the number of
lesions reported.
To evaluate the overall study response rate, the study confirmed response
rate was calculated using all reported lesions for each patient and also calcu-
lated using only the longest one to five lesions. Patients were included in this
analysis if they had at least two evaluations.
A sensitivity analysis was performed in patients that reported five or
more lesions. This analysis was conducted to evaluate the end points in those
patients who have the greatest opportunity for differential response status
based on the number of lesions considered.
RESULTS
The median number of lesions measured for pre-RECIST studies did
not differ from post-RECIST studies (median  2). In the pre-
RECIST and the post-RECIST trials, 5% (n  108) of patients had five
or more lesions reported. The percentage of patients with five or more
lesions did not differ by cooperative group. Figure 1 presents the
distribution of number of lesions measured at baseline.
The agreement between the objective status determined using all
lesions versus the objective status at each cycle determined by using
only the longest one, two, or three lesions was high. For cycle 2, there
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was 93% agreement (1,164 of 1,254) using the longest lesion as com-
pared to using all reported lesions, 98% agreement (1,241 of 1,263)
using the longest two lesions, and 99.8% agreement (1,265 of 1,268)
using the longest three lesions. These results were consistent over the
course of treatment. (Fig 2). In order to further examine the disagree-
ments, Table 1 provides objective status when including all lesions as
compared to the longest two for treatment cycles 1 and 2 respectively.
For cycle 1 data, 1% of the patients had an improved objective status
when considering only the longest two lesions and 0.7% had a decline.
This was similar for cycle 2 with 1.3% improved and 0.4% with a
decline. We also examined the agreement rates by number of baseline
lesions reported, assessment method, and disease site (Table 2). Re-
sults were similar across all factors considered.
The per patient agreement between confirmed response status
when considering only the longest, longest two and longest three
lesions compared to all lesions reported was also high. Considering
only the longest lesion resulted in 96% agreement (2,012 of 2,103),
longest two resulted in 99% agreement (2,079 of 2,104), and longest
three resulted in 99.8% agreement (2,100 of 2,105), all as compared to
the confirmed response status when considering all reported lesions.
Tumor progression was reported in 1,719 patients. Of these, 35%
(n  602) reported tumor progression based on new lesions or clinical
deterioration, 39% (n  670) went off therapy without progression
due to treatment completion, adverse events, refusal or other reasons,
but reported progression during the long-term follow-up portion of
the trial where measurements are not routinely collected and 26%
(n  447) reported progression based on tumor measurements.
The agreement rate on the cycle of disease progression based on
consideration of the longest lesion, longest two lesions and longest
three lesions compared to all lesions reported was also high, particu-
larly when the longest two or three lesions were considered. Compared
to all reported lesions, 91% agreement (1,552 of 1,701) was obtained
based on the single longest lesion, with the longest two lesions, 97%
agreement (1,665 of 1,716), and 99% agreement (1,705 of 1,718) when
the longest three lesions were considered.
A large percentage of patients were reported to have a small
number of lesions, thus the estimate of a rate of agreement obtained
from a comparison of end points based on all lesions versus the longest
one, two, or three lesions could be overly optimistic. We therefore
evaluated the same end points in the subset of patients who reported
five or more lesions, as this subset of 108 patients (5% of the total) has
the greatest opportunity for differential response status. The metric of
objective status by cycle was difficult to evaluate as small patient
numbers were available for any given single cycle (Table 2). For the
confirmed response and cycle of progression end points, the agree-
ment rates remained high. The confirmed response agreement rates
were 93% (83 of 89) when considering the longest single lesion, 93%
(83 of 89) when considering the longest two, and 98% (87 of 89) when
considering the longest three compared to all reported lesions. Re-
garding cycle of progression, again the agreement rates were high
when considering the longest two or three lesions. The agreement
rates are 82% (65 of 79) when considering the longest single lesion,
86% (68 of 79) when considering the longest two, and 89% (70 of 79)
when considering the longest three lesions.
Lastly, we compared the overall study response rate that would
have been estimated if for each study, the patient level response had
been determined using just each patient’s longest two lesions. In the 12
pre-RECIST trials, the largest absolute difference between the study
level response rate using only two lesions to using all reported lesions
was 1%, and the largest absolute difference in the overall study re-
sponse rate for the 20 post-RECIST trials was 3%, with all but three
trials showing no difference in overall response rate (Tables 3 and 4).
DISCUSSION
In this pooled analysis, we evaluated the value added as a result of
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Fig 1. Number of lesions measured at baseline. RECIST, Response Evaluation
Criteria in Solid Tumors.
































Cycle 1 (n = 409) Cycle 2 (n = 1,263) Cycle 3 (n = 703)
Longest 2 Longest 3
Fig 2. Agreement rates: objective status.




CR PR Stable PROG
1 (n  409)
CR 3 0 0 0
PR 0 66 1 0
Stable 0 2 228 3
PROG 0 0 2 104
2 (n  1,263)
CR 34 0 0 0
PR 1 287 4 0
Stable 0 9 662 1
PROG 0 1 6 258
Abbreviations: CR, complete response; PR, partial response; PROG, progression.
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therapies in more than 2,300 patients from 32 phase II/III clinical
trials. Based on our data, excellent concordance per patient is
observed in key trial end points using the measurements from two
lesions per patient compared to all lesions. Similarly, at the study
level, assessing more than two lesions does not alter the determi-
nation of response rate. This data strongly support the consider-
ation of a revision for RECIST. Such simplification would enhance
the utility of RECIST.
Mazumdar et al5 and Schwartz et al6 have recently presented a
theoretical approach to assessing the minimum number of tumors
required for assessing treatment response. Based on their model,
they proposed six lesions be measured, based on a consideration
that a  20% increment in variability is unacceptable. We note that
the selection of six lesions exceeds our recommendation of two,
and this may be due to the use of strictly tumor measurements to
define progression. We found a relatively low percentage of pa-
tients actually manifested progression based on tumor measure-
ments (26%). Tumor progression was more frequently reported
based on new lesions and clinical deterioration (35%). This may
imply that treatment fails because of emergence of resistant clones
or that it is easier to report new lesions rather than measure existing
ones, unfortunately our data collection methods did not allow us to
distinguish between these possibilities. It is also difficult to deter-
mine if symptomatic deterioration is intertwined with treatment
toxicity as again this data was not collected. The remaining 39% of
patients went off therapy without progression due to treatment
completion, adverse events, or refusal. These factors contribute to
the high rate of agreement specifically in TTP and overall study
response rate when only two lesions are assessed compared to all
lesions measured.
Table 2. Agreement Rates: Objective Status by Factors
Parameter
Lesion
Longest Longest 2 Longest 3
No. % No. % No. %
No. of baseline lesions
1 538/538 100.0 538/538 100.0 538/538 100.0
2 345/385 89.6 391/391 100.0 391/391 100.0
3 175/203 86.2 192/207 92.3 206/206 100.0
4 71/83 85.5 80/87 92.0 86/88 97.7
5 35/45 77.8 42/45 93.3 44/45 97.8
Assessment method
CT 1,021/1,097 93.1 1,086/1,106 98.2 1,104/1,106 99.8
CXR 45/45 100.0 47/47 100.0 47/47 100.0
PE 32/35 91.4 34/35 97.1 35/35 100.0
Mix 37/44 84.1 45/48 93.8 47/48 97.9
Other† 29/33 87.9 31/32 96.9 16/16 100.0
Disease
Breast 159/168 94.6 166/170 97.6 170/170 100.0
GI 728/785 92.7 780/793 98.4 791/794 99.6
Lung 243/264 92.0 260/268 97.0 267/267 100.0
Other 34/37 91.9 37/37 100.0 37/37 100.0
Abbreviations: CT, computed tomography; CXR, chest x-ray; PE, physical examination; Mix, mixture of imaging techniques.
Using cycle 2 agreement data.
†Other: magnetic resonance imaging (n  12), ultrasound (n  4), and unknown (n  17).
Table 3. Response Rates in Pre–Response Evaluation Criteria in Solid Tumors Studies




All Lesions Longest 2 Lesions No. %
N9741 GI 1,022 31 32 1 21 2.1
983252 Breast 56 71 71 0 0 0.0
974651 GI 34 56 56 0 0 0.0
982052 Lung 29 45 45 0 0 0.0
N9841 GI 246 20 20 0 0 0.0
982452 Lung 102 19 19 0 2 2.0
984351 GI 38 13 13 0 0 0.0
983253 Breast 21 10 10 0 0 0.0
982453 Lung 26 8 8 0 0 0.0
983251 Breast 21 5 5 0 0 0.0
972451 Lung 45 0 0 0 0 0.0
NOTE. Studies with N  20.
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Zacharia et al7 also undertook a similar evaluation of the optimal
number of lesions to be measured to assess response in patients un-
dergoing chemotherapy for colon cancer metastases to the liver. Al-
though their analysis was restricted to patients with colon cancer
metastases to the liver and was quite small (n  30), they also suggest
that it may be possible to reduce the number of lesions measured in
clinical trials. Patients utilized for the Zachareia et al analysis were
recruited prospectively, while our analysis included data from actual
phase II/III clinical trials. We purposely included all modes of assess-
ment, and trials across several disease sites and cooperative groups as
we sought to ensure that our analysis reflected the real data encoun-
tered when evaluating tumor response.
In a recent article, Eisenhauer summarizes the accomplishments
of RECIST and outlines the areas that need attention.8 She concluded
that the minimum number of lesions to assess antitumor activity was
likely fewer than the current 10 lesions, but indicated that little data
was available to base a revised recommendation.8 Our pooled analysis
was undertaken in a large sample of more than 2,300 patients across 32
trials and provides the data needed to support such revisions. We
found that for the majority of patients being enrolled onto these
clinical trials, a relatively small number of lesions were reported (me-
dian  2). It is unclear if this is representative of the larger population
of oncology patients, or if patients who tend to have more lesions are
less likely to enroll on clinical trials due to the impact of tumor burden
on their performance status, are less willing to participate in clinical
trials, have physicians less likely to place them on clinical trials due to
the increase in workload, or have additional lesions that were not
reported on the case report forms. We found that the agreement rate
for the typical trial end points assessed in oncology was very high when
comparing the longest two lesions to all lesions reported. These rates
remain high when considering only those patients with five or more
reported lesions.
There are several limitations to the analyses. The data were largely
from one cooperative group. A relatively small number of patients had
a large number of lesions measured. The findings are also limited to
GI, breast, and lung cancer, as the majority of our data came from
those tumor types. CT scanning was the modality used to assess tumor
measurements most often. While these factors limit the generalizabil-
ity of our conclusions, these three disease sites are among the most
common sites for the testing of new agents, and are most often fol-
lowed by CT scans. Another limitation is that the number of measur-
able lesions may potentially be under-reported in cooperative group
studies. The presence and potential impact on such under-reporting
cannot be assessed in this data. Thus, while our analysis cannot dem-
onstrate the concordance between measuring a small number of le-
sions versus some unknown truth we feel that this data does allow the
conclusion that within the context of current clinical trial practice,
assessing a smaller number of lesions will not impact trial outcomes.
There have been many recent proposals for improvement in
evaluation of tumor activity, including use of continuous tumor mea-
surements;9 however, at this time, RECIST remains the standard and
therefore these results remain highly relevant. If our results can be
confirmed in other data sets, RECIST guidelines should be re-
evaluated to allow the observation of two lesions to provide an ade-
quate measure of antitumor activity.
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Table 4. Response Rates for Post–Response Evaluation Criteria in Solid Tumors Studies




All Lesions Longest 2 No. %
N0043 GI 38 11 8 3 1 2.6
N9921 Lung 50 12 14 2 1 2.0
N9932 Breast 48 60 60 0 0 0.0
N9941 GI 46 26 26 0 0 0.0
N0026 Lung 37 14 14 0 0 0.0
N0021 Mesothelioma 21 10 10 0 0 0.0
N0022 Lung 54 6 6 0 0 0.0
N0032 Breast 20 5 5 0 0 0.0
N0031 Breast 23 4 4 0 0 0.0
N0042 GI 26 4 4 0 0 0.0
N9946 GI 35 3 3 0 0 0.0
N9975 Melanoma 27 0 0 0 0 0.0
NOTE. Studies with N  20.
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